{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2Ff1fba511-42c9-4886-93cc-0a71ec1056a1","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/f1fba511-42c9-4886-93cc-0a71ec1056a1\"></iframe>","title":"What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma","description":"Prof Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by Dr Neil Love.","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.png"}